Could Eli Lilly Leapfrog Biogen in This Market?

Could Eli Lilly Leapfrog Biogen in This Market?

Submitted by admin on November 17, 2021 - 10:26am
Source: 
Motley Fool
News Tags: 
Eli Lilly
Biogen
donanemab
Alzheimer's disease
Aduhelm
Headline: 
Could Eli Lilly Leapfrog Biogen in This Market?
snippet: 
  • Eli Lilly is seeking regulatory approval for its potential Alzheimer's disease medicine, donanemab.
  • The pharma giant is also planning a study to compare donanemab to Biogen's Aduhelm.
  • Biogen may currently have the upper hand in this market, but don't count Eli Lilly out yet.

Do Not Allow Advertisers to Use My Personal information